GlassScriptPhysician profile
Darryl W Hein
NPI 1124077227
$2,324.88
in general payments reported to CMS, 2019-2025
33 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $131 · 2023: $482 · 2024: $701 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.96 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $309.29 | 2023-2025 | |
| Glaxosmithkline, LLC. | $293.57 | 2023-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Amgen INC. | $240.92 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $129.90 | 2019-2024 | Farxiga, Airsupra |
| Mylan Specialty L.P. | $123.36 | 2019 | |
| Merck Sharp & Dohme LLC | $99.64 | 2019-2025 | Gardasil 9, Belsomra, M-M-R II |
| Philips North America LLC | $94.83 | 2019-2025 | Vest Therapy Und, (8874) Incourage |
| Lilly USA, LLC | $93.32 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $92.13 | 2019-2020 | |
| Bausch Health US, LLC | $90.22 | 2020-2025 | Aplenzin, Wellbutrin |
| Novo Nordisk INC | $76.67 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Electromed, INC. | $71.38 | 2019-2023 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $71.28 | 2024-2025 | |
| Amarin Pharma, INC. | $66.28 | 2019 | |
| Esperion Therapeutics, INC. | $48.11 | 2025 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $43.75 | 2024 | Apretude |
| Edwards Lifesciences Corporation | $41.05 | 2024 | Sapien 3 Ultra Resilia |
| Exact Sciences Corporation | $40.79 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $30.22 | 2019 | |
| Sanofi Pasteur INC. | $26.79 | 2023 | |
| Insmed, INC. | $26.64 | 2023 | Arikayce |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.05 | 2025 | Xifaxan |
| Nabriva Therapeutics, Plc | $22.87 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.70 | 2019 | |
| Cmp Pharma, INC. | $20.64 | 2023 | Tadliq, Liqrev, Atorvaliq |
| Si-Bone, INC. | $20.34 | 2023 | |
| Therapeuticsmd, INC. | $19.29 | 2019 | |
| Allergan, INC. | $17.93 | 2020 | |
| Seqirus USA INC | $15.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.66 | 2024 | |
| Rgh Enterprises LLC | $13.60 | 2024 | |
| Genentech USA, INC. | $13.31 | 2019 | |
| Abbvie INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Hein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.